We have been able to develop peptide innovation in a number of disease indications and applications through out strategic partners and the results are astounding every time!
NuvoBio has been focusing research and development on three key promising peptide therapeutics:
In vivo active anti-fungal peptide (NeoPeptix) targeting the SSA1 cell wall protein, offering a novel treatment for Cryptococcus neoformans infection.
Precision-designed peptide inhibitor for SMYD3 KMT, outperforming market leaders with cell activity and potency in treating ras-driven cancers.
Explore our library of potent SHP2 phosphatase inhibitors revolutionizing RTK-driven cancer treatment with precision and efficacy.